Marshall Edwards, Inc. (NASDAQ:MSHL)
CAPS Rating:
A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.
The Official Website of the Long-Term Investor
A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK